About: SARS-CoV-2 qRT-PCR Ct value distribution in Japan and possible utility of rapid antigen testing kit

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 qRT-PCR Ct value distribution in Japan and possible utility of rapid antigen testing kit Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV-2 qRT-PCR Ct value distribution in Japan and possible utility of rapid antigen testing kit
Creator	Mori, Masatoshi Omi, Kazuya Takeda, Yuta
Source	MedRxiv
abstract	The exact pathology of COVID-19 remains mostly unclear, and accurate epidemiological understanding and rapid testing are crucial to overcome this disease. Several types of nucleic acid tests (NAT) have been used in Japan, but information about the viral RNA load, determined by Ct values, of the patients is limited due to the small number of patients tested in each clinical institution and lack of standardization of the testing kits. We have been performing the qRT-PCR tests established by NIID, and the mean Ct value distribution of 62 cases, which are deemed (first-visit) patients, among the total of 88 positive cases tested in a 4-day window of early April, was 24.9 with SD=5.45. Recently approved antigen testing kits were also used in the same samples (62 positives) along with 100 negative cases, and it revealed the positive predictive value of 80.6% and negative predictive value of 100%, with an overall agreement rate of 92.6%. These results indicate that a certain number of patients with lower Ct values, existed in Japan when SARS-CoV-2 virus started to spread. The newly approved rapid antigen testing kit will be a useful tool to identify such populations rapidly.
has issue date	2020-06-19(xsd:dateTime)
bibo:doi	10.1101/2020.06.16.20131243
has license	medrxiv
sha1sum (hex)	580054637e694b91830a504a96ba5ad5176855dc
schema:url	https://doi.org/10.1101/2020.06.16.20131243
resource representing a document's title	SARS-CoV-2 qRT-PCR Ct value distribution in Japan and possible utility of rapid antigen testing kit
resource representing a document's body	covid:580054637e694b91830a504a96ba5ad5176855dc#body_text
is schema:about of	named entity 'remains' named entity 'patients' named entity 'tested' named entity 'virus' named entity 'testing' named entity 'STARTED' named entity 'RIGHTS' named entity 'DUE TO' named entity 'RATE' named entity 'SMALL' named entity 'RAPID' named entity 'INSTITUTION' named entity 'UNCLEAR' named entity 'LIMITED' named entity 'NUMBER OF PATIENTS' named entity 'PATIENTS' named entity 'PREPRINT' named entity 'predictive' named entity 'RNA' named entity 'testing' named entity 'load' named entity 'April' named entity 'patients' named entity 'total' named entity 'number' named entity 'patients' named entity 'cases' named entity 'viral' named entity 'Japan' named entity 'qRT-PCR' named entity 'testing kits' named entity 'antigen' named entity 'epidemiological' named entity 'Japan' named entity 'qRT-PCR' named entity 'accurate' named entity 'antigen' named entity 'antigen' named entity 'SARS-CoV-2' named entity 'qRT-PCR' named entity 'antigen' named entity 'follow-up' named entity 'peer review' named entity 'preprint' named entity 'Fujirebio' named entity 'antigen' named entity 'virus' named entity 'medRxiv' named entity 'COVID-19' named entity 'antigen' named entity 'clinical testing' named entity 'peer review' named entity 'NAT' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'tested positive' named entity 'SARS-CoV2' named entity 'SARS-CoV-2' named entity '6 million' named entity 'SARS-CoV-2' named entity 'influenza infection' named entity 'SARS-CoV-2' named entity 'qRT-PCR' named entity 'qRT-PCR' named entity 'COVID' named entity 'antigen' named entity 'rapid antigen test' named entity 'epidemic' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'rapid antigen test' named entity 'medRxiv' named entity 'Real-time PCR' named entity 'Nasopharyngeal swabs' named entity 'Pathogen' named entity 'Wuhan' named entity 'peer review' named entity 'antigen' named entity 'pathology' named entity 'pathology' named entity 'patients' named entity 'values' named entity 'tests'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software